RPRX Quote, Financials, Valuation and Earnings

Geron has a net margin of 96.33% compared to Royalty Pharma PLC's net margin of -93.55%. Royalty Pharma PLC's return on equity of 11.56% beat Geron's return on equity of -67.86%.

Royalty Pharma PLC has a consensus price target of $40.66, signalling upside risk potential of 37.88%. On the other hand Geron has an analysts' consensus of $7.61 which suggests that it could grow by 140.1%. Given that Geron has higher upside potential than Royalty Pharma PLC, analysts believe Geron is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron has a beta of 0.551, suggesting its less volatile than the S&P 500 by 44.885%.

Royalty Pharma PLC has a quarterly dividend of $0.21 per share corresponding to a yield of 2.85%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 31.58% of its earnings as a dividend. Geron pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $564.7M, which are larger than Geron quarterly revenues of $28.3M. Royalty Pharma PLC's net income of $544M is higher than Geron's net income of -$26.4M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 11.56x while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 7.76x versus 67.60x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 96.33% compared to Royalty Pharma PLC's net margin of -104.98%. Royalty Pharma PLC's return on equity of 11.56% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Royalty Pharma PLC has a consensus price target of $40.66, signalling upside risk potential of 37.88%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.32 which suggests that it could grow by 83.26%. Given that Ionis Pharmaceuticals has higher upside potential than Royalty Pharma PLC, analysts believe Ionis Pharmaceuticals is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.485%.

Royalty Pharma PLC has a quarterly dividend of $0.21 per share corresponding to a yield of 2.85%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 31.58% of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $564.7M, which are larger than Ionis Pharmaceuticals quarterly revenues of $133.8M. Royalty Pharma PLC's net income of $544M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 11.56x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 7.76x versus 6.08x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 96.33% compared to Royalty Pharma PLC's net margin of 36.03%. Royalty Pharma PLC's return on equity of 11.56% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Royalty Pharma PLC has a consensus price target of $40.66, signalling upside risk potential of 37.88%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,042.95 which suggests that it could grow by 49.66%. Given that Regeneron Pharmaceuticals has higher upside potential than Royalty Pharma PLC, analysts believe Regeneron Pharmaceuticals is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Royalty Pharma PLC has a quarterly dividend of $0.21 per share corresponding to a yield of 2.85%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 31.58% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $564.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Royalty Pharma PLC's net income of $544M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Royalty Pharma PLC's price-to-earnings ratio is 11.56x while Regeneron Pharmaceuticals's PE ratio is 17.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 7.76x versus 5.79x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Walgreens Boots Alliance has a net margin of 96.33% compared to Royalty Pharma PLC's net margin of -8%. Royalty Pharma PLC's return on equity of 11.56% beat Walgreens Boots Alliance's return on equity of -43.52%.

Royalty Pharma PLC has a consensus price target of $40.66, signalling upside risk potential of 37.88%. On the other hand Walgreens Boots Alliance has an analysts' consensus of $10.97 which suggests that it could fall by -7.6%. Given that Royalty Pharma PLC has higher upside potential than Walgreens Boots Alliance, analysts believe Royalty Pharma PLC is more attractive than Walgreens Boots Alliance.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Walgreens Boots Alliance has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.445%.

Royalty Pharma PLC has a quarterly dividend of $0.21 per share corresponding to a yield of 2.85%. Walgreens Boots Alliance offers a yield of 8.5% to investors and pays a quarterly dividend of $0.25 per share. Royalty Pharma PLC pays 31.58% of its earnings as a dividend. Walgreens Boots Alliance pays out -14.59% of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $564.7M, which are smaller than Walgreens Boots Alliance quarterly revenues of $37.5B. Royalty Pharma PLC's net income of $544M is higher than Walgreens Boots Alliance's net income of -$3B. Notably, Royalty Pharma PLC's price-to-earnings ratio is 11.56x while Walgreens Boots Alliance's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 7.76x versus 0.07x for Walgreens Boots Alliance. Usually stocks with elevated PS ratios are considered overvalued.